Biomarkers of Perioperative Glymphatic Dysfunction

Abstract

Perioperative glymphatic dysfunction has emerged as a significant concern in perioperative neurobiology, with increasing evidence linking impaired cerebrospinal fluid (CSF) clearance to neurocognitive complications following surgery. Recent advances in biomarker discovery have opened new avenues for assessing glymphatic system integrity and dysfunction. This review synthesizes current knowledge on the identification and clinical significance of biomarkers associated with perioperative glymphatic dysfunction, delving into their mechanisms, diagnostic utility, and implications for perioperative patient management.

Introduction

The glymphatic system, a brain-wide perivascular network facilitating CSF and interstitial fluid exchange, plays a crucial role in metabolic waste clearance. During the perioperative period, glymphatic dysfunction has been implicated in the development of postoperative neurocognitive disorders, including delirium and delayed cognitive recovery. Understanding the biomarkers that signal perioperative glymphatic impairment is essential for risk stratification, early intervention, and the design of neuroprotective strategies. This article explores the current landscape of perioperative glymphatic dysfunction biomarkers, integrating recent research findings and their translational relevance to clinical care.

Epidemiology / Disease Burden

Perioperative neurocognitive disorders (PNDs) affect up to 50% of elderly patients undergoing major surgery, with reported incidence varying based on patient age, comorbidities, and surgical complexity. Glymphatic dysfunction is increasingly recognized as a contributing factor to these outcomes. Large-scale epidemiological studies have demonstrated a correlation between perioperative glymphatic impairment assessed indirectly via imaging and molecular markers and the incidence of PNDs, particularly in cardiac, orthopedic, and neurosurgical populations. The burden is substantial, with increased perioperative neurocognitive morbidity translating into prolonged hospitalizations, higher healthcare costs, and decreased quality of life.

Pathophysiology

The glymphatic system relies on aquaporin-4 (AQP4) water channels expressed on astrocytic endfeet to facilitate convective CSF flow through the brain parenchyma. Perioperative factors such as anesthesia, systemic inflammation, microvascular dysfunction, and changes in intracranial pressure disrupt AQP4 polarization and perivascular flow, resulting in impaired metabolic waste clearance. Accumulation of neurotoxic proteins including amyloid-beta and tau has been observed in animal models of perioperative glymphatic dysfunction. These pathophysiological changes may precipitate or exacerbate neurocognitive decline, particularly in vulnerable populations.

Risk Factors

Risk factors for perioperative glymphatic dysfunction include advanced age, preexisting cognitive impairment, cardiovascular comorbidities (e.g., hypertension, atherosclerosis), sleep disorders, prolonged anesthesia, and high intraoperative blood loss. Genetic predispositions, such as APOE4 allele carriage, may also modulate glymphatic efficiency and susceptibility to perioperative dysfunction. Identifying patients with these risk factors facilitates targeted monitoring and intervention.

Clinical Features

Clinical manifestations of perioperative glymphatic dysfunction are often nonspecific and overlap with broader categories of PNDs. Common features include acute delirium, delayed emergence from anesthesia, inattention, disorientation, memory deficits, and executive dysfunction. In severe cases, patients may develop persistent cognitive impairment or even postoperative cognitive dysfunction (POCD), which can persist for weeks to months following surgery. Subtle motor disturbances and sleep-wake cycle abnormalities have also been reported, reflecting the glymphatic system's role in circadian regulation.

Diagnosis

Direct assessment of glymphatic function in humans remains challenging. However, several biomarkers have been proposed for perioperative evaluation. Neuroimaging techniques such as diffusion tensor imaging (DTI) and dynamic contrast-enhanced MRI enable visualization of glymphatic flow and perivascular spaces. CSF biomarkers include elevated levels of amyloid-beta, tau, neurofilament light chain (NfL), and S100B protein. Recent studies suggest that plasma levels of glial fibrillary acidic protein (GFAP) and exosomal AQP4 may reflect glymphatic integrity. Combining these biomarkers with clinical assessment and neuropsychological testing enhances diagnostic accuracy.

Treatment & Management

Management strategies for perioperative glymphatic dysfunction focus on optimizing perioperative care to preserve glymphatic flow. Interventions include maintaining stable hemodynamics, minimizing intraoperative hypoxia and hypercapnia, and implementing multimodal analgesia to reduce opioid exposure. Perioperative sleep optimization and early mobilization may support glymphatic clearance. In patients with identifiable dysfunction, close neurocognitive monitoring and early rehabilitation interventions are recommended. Pharmacological approaches targeting AQP4 or neuroinflammation are under investigation but not yet standard of care.

Recent Advances / Emerging Therapies

Advances in molecular and imaging biomarker discovery have revolutionized the study of glymphatic dysfunction. Novel CSF and blood-based biomarkers, such as extracellular vesicles containing glymphatic cargo, are being explored for their diagnostic and prognostic potential. Noninvasive imaging modalities, including ultra-fast MRI sequences and PET tracers for AQP4, offer real-time assessment of glymphatic dynamics. Experimental therapies targeting glymphatic modulation such as low-frequency transcranial stimulation and agents that enhance AQP4 function are under preclinical and early clinical evaluation.

Guideline Recommendations

Current perioperative guidelines emphasize the importance of neurocognitive assessment and individualized risk stratification in high-risk populations. While routine biomarker testing for glymphatic dysfunction is not yet established, emerging evidence suggests that integrating biomarker-based risk assessment may enhance perioperative neuroprotection strategies. Guidelines recommend multidisciplinary perioperative planning, including anesthetic techniques that minimize glymphatic impairment and postoperative protocols to promote neurocognitive recovery.

Conclusion

Biomarkers of perioperative glymphatic dysfunction represent a promising frontier in perioperative medicine, offering new opportunities for early detection, risk stratification, and targeted intervention in patients at risk of neurocognitive complications. Ongoing research into the mechanistic underpinnings and clinical applications of glymphatic biomarkers will inform future guidelines and improve perioperative outcomes for vulnerable patient populations.